{"entity":{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","aka":[],"tldr":"First author of the revumenib trial that created the menin inhibitor class for acute leukaemia.","summary":"Ghayas Issa led and was first author of the AUGMENT-101 phase 1 report in Nature showing the menin inhibitor revumenib produces remissions in heavily pretreated KMT2A-rearranged and NPM1-mutant acute leukaemia, and of the pivotal phase 2 analysis that led to its 2024 approval. He leads menin inhibitor combination trials and studies of resistance (MEN1 mutations) at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Issa%20GC%5BAuthor%5D%20revumenib%20menin"}],"tags":["aml","menin","targeted-therapy"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":[],"targets":["menin"],"drugs":["revumenib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["augment-101"],"people":[],"bottlenecks":[],"keyPapers":["paper-augment-101-revumenib-menin-nature-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Acute leukaemia","Menin inhibitors","KMT2A-rearranged leukaemia","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Issa%20GC%5BAuthor%5D%20revumenib%20menin"}],"papers":[{"title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-05812-3"},{"title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","journal":"JCO","year":2025,"doi":"10.1200/JCO.24.00826"},{"title":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","journal":"Nature","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AUGMENT-101%20revumenib%20menin%20inhibitor%20KMT2A%20NPM1%20Issa%20Nature%202023"}],"orcid":"0000-0002-4339-8683"},"route":"/people/ghayas-issa/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/"}],"drug":[{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/"}],"paper":[{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}]}}